Stay updated on SubQ Efgartigimod in CIDP Clinical Trial
Sign up to get notified when there's something new on the SubQ Efgartigimod in CIDP Clinical Trial page.

Latest updates to the SubQ Efgartigimod in CIDP Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThis page shows a minor site update: a new Revision: v3.3.2 was added and the previous Revision: v3.3.1 was removed. The change appears to affect only UI/versioning text and does not modify the study content, eligibility criteria, enrollment, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check24 days agoChange DetectedPublication notes now say PubMed publications are automatically filled and may not be about the study, alongside a new Revision: v3.3.1. The old PubMed text has been replaced with this updated note.SummaryDifference0.0%

- Check32 days agoChange DetectedAdded Tainan, Taiwan to the study locations; removed Tainan City, Taiwan from the locations list.SummaryDifference0.1%

- Check39 days agoChange DetectedNo significant changes detected between the two screenshots. The page content and layout appear unchanged.SummaryDifference0.2%

- Check75 days agoChange DetectedAdd: new operating-status notice and a new version tag v3.2.0. Delete: removal of a specific resource entry (Chronic inflammatory demyelinating polyradiculoneuropathy) and an older version tag v3.0.2. Overall, the page now signals current status and a more recent release, with a different resource mention.SummaryDifference2%

- Check82 days agoChange DetectedRemoved four MedlinePlus topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs); overall breadth of content is reduced.SummaryDifference0.2%

Stay in the know with updates to SubQ Efgartigimod in CIDP Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Efgartigimod in CIDP Clinical Trial page.